Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY21 Earnings Presentation
18 slides from Aurobindo Pharma's earnings presentation, Aug 12, 2020
Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
AUROBINDO August 12, 2020 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, 8andra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROPHARM
Slide 2: Aurobindo Pharma Limited Q1FY21 Earnings Presentation
Aurobindo Pharma Limited Q1FY21 Earnings Presentation 12th August 2020
Slide 3: Disclaimer
Aurobindo Pharma Limited – Earnings Presentation 2 Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of
Slide 4: Index
Aurobindo Pharma Limited – Earnings Presentation 3 Index 1 Q1FY21 Financial & Business Highlights 2 Financial Performance 3 Filings Snapshot
Slide 5: Q1 FY21 Financial & Business Highlights
1 Q1 FY21 Financial & Business Highlights 4
Slide 6: Consolidated Financial & Business Highlights – Q1 FY21
Aurobindo Pharma Limited – Earnings Presentation 5 Consolidated Financial & Business Highlights – Q1 FY21 In Rs Cr Revenue EBITDA Profit After Tax 8.8% 9.7% 22.8% 1,257 5,925 781 636 5,445 1,146 21.1% 21.2% Q1FY20 Q1FY21 Q1FY20 Q1FY21 Q1FY20 Q1FY21 EBITDA Margin
Slide 7: Consolidated Financial & Business Highlights – Q1FY21
Aurobindo Pharma Limited – Earnings Presentation 6 Consolidated Financial & Business Highlights – Q1FY21 Revenue from operations at Rs. 5,924.8 crore, witnessed a growth of 8.8% YoY EBIDTA before Forex and Other income at Rs. 1,257.4 crore, an increase of 9.7% YoY; EBITDA margin is at 21.2% Net Prof
Slide 8: Consistent Quarterly Performance
Aurobindo Pharma Limited – Earnings Presentation 7 Consistent Quarterly Performance Revenue (Rs Cr) US Revenue ($ Mn) 5,895 6,158 5,925 418 413 5,600 404 412 5,270 5,292 5,445 387 4,751 339 353 4,250 318 282 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q3FY20 Q4FY20 Q1FY21 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q
Slide 9: US Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 8 US Business Performance Highlights In Rs Cr Revenue Revenue Mix Q1 FY21 3,107 Injectables* Orals 2,990 12.3% 66.8% Total Injectables 18.5% 2,688 Branded Oncology 6.2% Dietary Supplements 12.4% Q1FY20 Q4FY20 Q1FY21 OTC 2.5% US Formulations • US reven
Slide 10: Europe, ARV, Growth Markets, API Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 9 Europe, ARV, Growth Markets, API Business Performance Highlights In Rs Cr Europe Revenues Growth Markets Revenues ARV Revenues API Revenues 1,653 377 425 780 382 756 1,392 313 732 319 1,322 290 Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20
Slide 11: Financial Performance
2 Financial Performance 10
Slide 12: Consolidated Financial Performance
Aurobindo Pharma Limited – Earnings Presentation 11 Consolidated Financial Performance Rs Cr Q1FY21 Q1FY20 (%) Chg Q4FY20 (%) Chg Revenue from operations 5,924.8 5,444.6 8.8 6,158.4 -3.8 Gross Profit 3,517.4 3,146.1 11.8 3,655.1 -3.8 Gross Margin 59.4% 57.8% 59.4% Overheads 2,260.0 1,999.7 13.0 2,31
Slide 13: Debt Profile
Aurobindo Pharma Limited – Earnings Presentation 12 Debt Profile Fx Loan US$ Mn Debt as on (Rs Crore) Mar-18 Mar-19 Mar-20 June-20 Closing Rate1 US$ = INR 65.17 69.155 75.6650 75.5050 731 1,006 733 633 Fx Loan restated in INR 4,766.9 6,959.0 5,549.2 4,776.0 Rupee Loan 4.1 8.1 16.9 0.6 248 Gross Debt
Slide 14: Financial Performance – 5 Year trend
Aurobindo Pharma Limited – Earnings Presentation 13 Financial Performance – 5 Year trend Rs. Crore FY16 FY17 FY18 FY19 FY20 Revenue 13,955 15,090 16,500 19,564 23,099 Gross Profit 7,793 8,656 9,747 10,851 13,363 Gross Profit Margin 55.8% 57.4% 59.1% 55.5% 57.9% EBITDA 3,188 3,434 3,789 3,952 4,864 E
Slide 15: Filings Snapshot
3 Filings Snapshot 14
Slide 16: US Filings Snapshot as on 30th Jun 2020
Aurobindo Pharma Limited – Earnings Presentation 15 US Filings Snapshot as on 30th Jun 2020 ANDA Filings Addressable Dermatology, Nasals and Opthalmic 410 Therapy ANDAs Market Size Includes ANDAs of Orals, OTC, 335 75 (US$ Bn) 59 CNS 102 23.2 Non - Injectables Injectables CVS 91 28.7 166 135 ARV** 4
Slide 17: Filing details
Aurobindo Pharma Limited – Earnings Presentation 16 Filing details As at As at As at As at As at As at As at As at As at Jun Category Approvals Mar 14 Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 June 19 Mar 20 20 Formulations US* 336 376 398 429 478 541 551 586 604 438 (FA: 410, TA:28) 2,615 Dossiers (291 Eu
Slide 18: Thank You
Thank You Investors Contact Investor Relations team ir@aurobindo.com 040-66725401